Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Health System and Reform In Lebanon - 2003


Health spending in Lebanon is growing rapidly and faster than GDP. The current financing and delivery arrangements, extensively described in this book, are responsible for the resulting poor value for money. Reform is needed to adapt the health system with financial constraints and changing demographic and epidemiological profiles, and to produce the desired health outcomes. Lebanon's experience in introducing reform measures within a pluralistic health system, is interesting for many EMR countries, which consider enhancing the private sector role in health care provision and financing. This book provides evidence that, in the absence of proper regulation, the public financing of private services feed the escalation of health expenditures, while private insurance takes full advantage of the weak regulation capability of the public administration. It provides an analysis of the health care market and assesses the impact of the supply and different payment mechanisms on the demand and the cost of medical services.

This book does not only target experts and health professionals but is also a useful reference for students in medical and public health schools. It exposes them to different approaches for evaluating a health system, comparing utilization rates and incurred expenses between financing agencies, and calculating national health accounts. Finally, it introduces different reform components, proposes their gradual integration and gives the global picture of change for the future. 

Contents:

Chapters:
 I-    The Challenging Context
 II-   Provision of Health Services
 III-  Financing of The Health System
 IV-   Characteristics of The Market
 V-    Evaluation of The Health System
 VI-   Health Sector Reform
 VII-  Health Financing Reform and Stakeholder Analysis
 
 
    2
    ...
ATC Name B/G Ingredients Dosage Form Price
J01DD08 SUPRAX B Cefixime (trihydrate) - 400mg 400mg Capsule 2,053,391 L.L
L04AX04 SOTIRA G Lenalidomide - 5mg 5mg Capsule 68,908,116 L.L
L04AX04 SOTIRA G Lenalidomide - 10mg 10mg Capsule 72,248,183 L.L
J01DD15 SEFARIN G Cefdinir - 300mg 300mg Capsule 1,494,353 L.L
L04AX04 SOTIRA G Lenalidomide - 15mg 15mg Capsule 76,208,289 L.L
L04AX04 SOTIRA G Lenalidomide - 25mg 25mg Capsule 76,719,234 L.L
R05CB06 SOLVAMUC SR G Ambroxol - 75mg 75mg Capsule 276,448 L.L
L01EX01 SUNITINIB AQVIDA G Sunitinib maleate - 12.5mg 12.5mg Capsule, hard 38,073,237 L.L
L01EX01 SUNITINIB AQVIDA G Sunitinib maleate - 50mg 50mg Capsule, hard 125,308,072 L.L
L01EA01 SAGITTA G Imatinib - 400mg 400mg Capsule, hard 51,723,840 L.L
L01EA01 SAGITTA G Imatinib - 100mg 100mg Capsule, hard 25,170,264 L.L
R03BB04 SPIRIVA WITH HANDIHALER B Tiotropium bromide - 18mcg 18mcg Capsule, inhalation 3,179,531 L.L
R03BB06 SEEBRI BREEZHALER B Glycopyronium Bromide - 50mcg 50mcg Capsule, inhalation 2,687,685 L.L
A03AA04 SPASMINE (Mebeverine HCl 200mg SR) G Mebeverine HCl - 200mg 200mg Capsule, slow release 712,876 L.L
L04AD01 SANDIMMUN NEORAL SOFT GELATIN B Ciclosporin - 50mg 50mg Capsule, soft gelatin 4,309,703 L.L
L04AD01 SANDIMMUN NEORAL SOFT GELATIN B Ciclosporin - 25mg 25mg Capsule, soft gelatin 2,385,320 L.L
L04AD01 SANDIMMUN NEORAL SOFT GELATIN B Ciclosporin - 100mg 100mg Capsule, soft gelatin 8,264,592 L.L
C05AA01 SEDIPROCT G Hydrocortisone - 500mg, Cinchocaine HCl - 500mg Cream 290,270 L.L
D10AX03 SKINOREN B Azelaic acid - 0.2g/g 0.2g/g Cream 722,987 L.L
D11AX22 SOOLANTRA B Ivermectin - 10mg/g 10mg/g Cream 2,154,180 L.L
D11AX22 SOOLANTRA B Ivermectin - 10mg/g 10mg/g Cream 1,053,573 L.L
D06BA01 SILVEDERMA G Silver sulfadiazine - 1% 10mg/g Cream 1,220,209 L.L
D06BA01 SILVEDERMA G Silver sulfadiazine - 1% 10mg/g Cream 494,534 L.L
D06BA51 SILVEZ PLUS G Silver sulfadiazine - , Chlorhexidine - Cream 349,399 L.L
R05DB13 SINECOD B Butamirate dihydrogenocitrate - 5mg/ml 5mg/ml Drops 287,582 L.L
S03AA30 SULFACHLOR G Sulfacetamide sodium - 110mg/ml, Chloramphenicol - 5mg/ml Drops solution 202,216 L.L
S01EC54 SIMBRINZA B Brinzolamide - 1%, Brimonidine tartrate - 0.2% Drops suspension 1,706,680 L.L
A03AX13 SIMETHICONE G Dimethicone - 2g/100ml 2g/100ml Emulsion 212,327 L.L
A07EC02 SALOFALK B Mesalazine - 4g/60ml 4g/60ml Enema 3,796,355 L.L
D10AF02 SPOTEX G Erythromycin - 4% 4% Gel 854,684 L.L
    2
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025